Argent BioPharma Limited (RGT.L)

GBp 6.0

(-7.69%)

EBITDA Summary of Argent BioPharma Limited

Argent BioPharma Limited's latest annual EBITDA in 2023 was -15.77 Million AUD , down -103.91% from previous year.
Argent BioPharma Limited's latest quarterly EBITDA in 2023 Q4 was -3.14 Million GBP , up 9.76% from previous quarter.
Argent BioPharma Limited reported an annual EBITDA of -7.73 Million AUD in 2022, down -9.16% from previous year.
Argent BioPharma Limited reported an annual EBITDA of -20.3 Million AUD in 2021, down -35.26% from previous year.
Argent BioPharma Limited reported a quarterly EBITDA of -3.48 Million GBP for 2023 Q2, down -0.29% from previous quarter.
Argent BioPharma Limited reported a quarterly EBITDA of N/A for 2022 FY, down -9.16% from previous quarter.

Annual EBITDA Chart of Argent BioPharma Limited (2023 - 2015)

Historical Annual EBITDA of Argent BioPharma Limited (2023 - 2015)

Year	EBITDA	EBITDA Growth
2023	-15.77 Million AUD	-103.91%
2022	-7.73 Million AUD	-9.16%
2021	-20.3 Million AUD	-35.26%
2020	-5.23 Million AUD	16.98%
2019	-6.3 Million AUD	-30.34%
2018	-1.6 Million GBP	-7.7%
2017	-8.56 Million GBP	-14.31%
2016	-3.93 Million GBP	-188.79%
2015	-1.36 Million GBP	0.0%

Year	EBITDA	EBITDA Growth
2023 Q4	-3.14 Million GBP	9.76%
2023 Q2	-3.48 Million GBP	-0.29%
2022 FY	- AUD	-9.16%
2022 Q4	-3.47 Million GBP	18.92%
2022 Q2	-4.28 Million GBP	-25.1%
2021 Q2	-2.26 Million GBP	-73.74%
2021 FY	- AUD	-35.26%
2021 Q4	-3.42 Million GBP	-50.89%
2020 Q4	-1.3 Million GBP	54.44%
2020 FY	- AUD	16.98%
2020 Q2	-2.86 Million GBP	20.47%
2019 FY	- AUD	-30.34%
2019 Q4	-3.6 Million GBP	0.0%
2018 FY	- GBP	-7.7%
2017 FY	- GBP	-14.31%
2016 FY	- GBP	-188.79%
2015 FY	- GBP	0.0%

Peer EBITDA Comparison of Argent BioPharma Limited

Name	EBITDA	EBITDA Difference